NO20050060L - Medikament for behandling av overaktiv blaere - Google Patents

Medikament for behandling av overaktiv blaere

Info

Publication number
NO20050060L
NO20050060L NO20050060A NO20050060A NO20050060L NO 20050060 L NO20050060 L NO 20050060L NO 20050060 A NO20050060 A NO 20050060A NO 20050060 A NO20050060 A NO 20050060A NO 20050060 L NO20050060 L NO 20050060L
Authority
NO
Norway
Prior art keywords
medication
treatment
overactive bladder
overactive
pharmaceutically acceptable
Prior art date
Application number
NO20050060A
Other languages
English (en)
Norwegian (no)
Inventor
Nico J Visser
Hiroshi Kajii
Nobuyuki Takiguchi
Rian Van Meeteren
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NO20050060L publication Critical patent/NO20050060L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20050060A 2002-06-07 2005-01-06 Medikament for behandling av overaktiv blaere NO20050060L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002166408 2002-06-07
PCT/JP2003/007149 WO2003103659A1 (ja) 2002-06-07 2003-06-05 過活動膀胱治療剤

Publications (1)

Publication Number Publication Date
NO20050060L true NO20050060L (no) 2005-03-04

Family

ID=29727628

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050060A NO20050060L (no) 2002-06-07 2005-01-06 Medikament for behandling av overaktiv blaere

Country Status (16)

Country Link
US (2) US20060035923A1 (ja)
EP (1) EP1552825A4 (ja)
JP (1) JP4466370B2 (ja)
KR (1) KR20050008795A (ja)
CN (1) CN100355419C (ja)
AR (1) AR040248A1 (ja)
AU (1) AU2003242166A1 (ja)
BR (1) BR0311414A (ja)
CA (1) CA2487899A1 (ja)
IL (1) IL165370A0 (ja)
MX (1) MXPA04012070A (ja)
NO (1) NO20050060L (ja)
PL (1) PL372560A1 (ja)
RU (1) RU2004135563A (ja)
TW (1) TW200408387A (ja)
WO (1) WO2003103659A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
EP1728791A4 (en) * 2004-03-25 2008-12-10 Astellas Pharma Inc COMPOSITIONS FOR SOLID PHARMACEUTICAL PREPARATION OF SOLIFENACIN OR BZW. A SALT OF IT
ZA200608614B (en) * 2004-03-25 2008-06-25 Astellas Pharma Inc Composition for solid pharmaceutical preparation of solifenacin or salt thereof
EP1832288B1 (en) * 2004-12-27 2012-06-20 Astellas Pharma Inc. Stable granular pharmaceutical composition of solifenacin or its salt
ES2387571T3 (es) * 2004-12-27 2012-09-26 Astellas Pharma Inc. Composición farmacéutica granulada estable de solifenacina o de su sal
CA2599158C (en) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
CA2697137A1 (en) * 2007-07-20 2009-01-29 Astellas Pharma Inc. Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly
PL2216021T3 (pl) 2007-11-02 2013-03-29 Astellas Pharma Inc Kompozycja farmaceutyczna do leczenia zespołu pęcherza nadreaktywnego
CA2709727A1 (en) * 2007-12-21 2009-07-02 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
EP2181707A1 (en) * 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
PL2394648T3 (pl) * 2009-02-04 2016-12-30 Kompozycja farmaceutyczna do podawania doustnego
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
KR102027912B1 (ko) * 2011-02-15 2019-10-02 지엘팜텍주식회사 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제
JP2015510928A (ja) * 2012-03-19 2015-04-13 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための延長放出製剤およびその使用方法
CN102743757A (zh) * 2012-07-09 2012-10-24 张家华 治疗膀胱流出道梗阻所致膀胱活动过度的药物
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN106265667B (zh) * 2015-05-18 2019-01-25 中国科学院生物物理研究所 一种氯喹的用途
CN106562968B (zh) * 2015-10-13 2019-08-13 南京华威医药科技集团有限公司 包含盐酸坦洛辛和琥珀酸索利那新的药物组合物
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
WO2001010436A1 (fr) * 1999-08-09 2001-02-15 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales destinees au traitement de l'uropathie inferieur
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法

Also Published As

Publication number Publication date
EP1552825A1 (en) 2005-07-13
IL165370A0 (en) 2006-01-15
JP4466370B2 (ja) 2010-05-26
TW200408387A (en) 2004-06-01
US20070270459A1 (en) 2007-11-22
CA2487899A1 (en) 2003-12-18
PL372560A1 (en) 2005-07-25
MXPA04012070A (es) 2005-03-07
KR20050008795A (ko) 2005-01-21
RU2004135563A (ru) 2005-06-10
US20060035923A1 (en) 2006-02-16
AU2003242166A1 (en) 2003-12-22
CN1658859A (zh) 2005-08-24
EP1552825A4 (en) 2009-11-25
WO2003103659A1 (ja) 2003-12-18
CN100355419C (zh) 2007-12-19
BR0311414A (pt) 2005-03-15
AR040248A1 (es) 2005-03-23
JPWO2003103659A1 (ja) 2005-10-06

Similar Documents

Publication Publication Date Title
NO20050060L (no) Medikament for behandling av overaktiv blaere
NO20032233L (no) Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
AR044923A1 (es) Imidazoquinolinas sustituidas con sulfonamida
NO20044054L (no) Administrering av midler for behandling av betennelse
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2003259381A1 (en) Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
AR032293A1 (es) Estuche farmaceutico
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
WO2006064228A3 (en) Thiazolopyramidine compounds for the modulation of chemokine receptor activity
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
NO20054320L (no) Terapeutisk middel mot hemoroidesykdom
NO20023111L (no) Utvortes preparat for behandling av pruritus
NO20064196L (no) Utvortes preparat for behandling av smertefulle hudskader
NO20054718L (no) Terapeutisk og/eller preventivt middel for kroniske hudsykdommer
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
HRP20050497B1 (en) Use of levocetirizine for the persistent allergic rhinitis
AU2003281257A1 (en) A novel use of rapamycin and structural analogues thereof
NO20050445L (no) Synergistisk interaksjon mellom abacavir og alovudin
NO20042586L (no) Behandlingsfremgangsmate
NO20050933L (no) Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application